Vinva Investment Management Ltd Increases Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Vinva Investment Management Ltd raised its stake in IQVIA Holdings Inc. (NYSE:IQV) by 9.4% during the 4th quarter, HoldingsChannel.com reports. The firm owned 9,110 shares of the medical research company’s stock after acquiring an additional 786 shares during the period. Vinva Investment Management Ltd’s holdings in IQVIA were worth $1,799,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in IQV. Synergy Asset Management LLC purchased a new position in IQVIA in the fourth quarter valued at approximately $33,000. Avior Wealth Management LLC increased its stake in IQVIA by 117.6% in the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 87 shares during the last quarter. Meeder Asset Management Inc. boosted its holdings in shares of IQVIA by 353.7% in the third quarter. Meeder Asset Management Inc. now owns 245 shares of the medical research company’s stock valued at $58,000 after acquiring an additional 191 shares during the period. Versant Capital Management Inc boosted its holdings in shares of IQVIA by 46.0% in the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock valued at $58,000 after acquiring an additional 93 shares during the period. Finally, SBI Securities Co. Ltd. acquired a new stake in shares of IQVIA in the fourth quarter valued at approximately $60,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Royal Bank of Canada reissued an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a report on Monday, February 10th. Barclays decreased their price objective on IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a report on Monday, February 3rd. William Blair reissued an “outperform” rating on shares of IQVIA in a report on Wednesday, December 11th. JPMorgan Chase & Co. decreased their price objective on IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a report on Tuesday, February 18th. Finally, BTIG Research lowered shares of IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. Five research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $249.05.

IQVIA Trading Down 1.5 %

NYSE:IQV opened at $184.13 on Friday. The company has a market capitalization of $32.46 billion, a PE ratio of 24.55, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 52-week low of $179.28 and a 52-week high of $256.29. The stock has a fifty day simple moving average of $195.30 and a 200-day simple moving average of $209.18.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.